{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:21:36Z","timestamp":1781263296756,"version":"3.54.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The goal of this study was to compare outcomes of patients with borderline and resectable pancreatic cancer treated with neoadjuvant stereotactic body radiation therapy (SBRT) versus fractionated chemoradiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with borderline or resectable pancreatic cancer treated with neoadjuvant intent between November 2011 and December 2017 were reviewed. The SBRT volume\/dose was 33 Gy in 5 fractions to gross tumor plus abutting vessel with or without 25 Gy in 5 fractions to pancreatic head\/body and celiac\/superior mesenteric artery. Fractionated chemoradiation volume\/dose was 50.4 Gy in 28 fractions to gross tumor, superior mesenteric\/celiac arteries, and enlarged lymph nodes with concurrent bolus 5-FU, leucovorin, oxaliplatin, irinotecan or gemcitabine\/nab-paclitaxel. Failure patterns, local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty-three patients were reviewed (18 SBRTs and 25 fractionated). Among patients who underwent resection, patients treated with fractionated chemoradiation had improved LRFS (12-month LRFS, 86% vs 62%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003) and PFS (median PFS, 23 months vs 11 months, <jats:italic toggle=\"yes\">P =<\/jats:italic> 0.006) compared with SBRT. There was no difference in overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Stereotactic body radiation therapy may result in inferior LRFS and PFS compared with fractionated chemoradiation, likely because of under coverage of high-risk vascular targets.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001602","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T09:07:59Z","timestamp":1594631279000},"page":"941-946","source":"Crossref","is-referenced-by-count":21,"title":["Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer"],"prefix":"10.1097","volume":"49","author":[{"given":"Michelle","family":"Barrord","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olugbenga","family":"Olowokure","sequence":"additional","affiliation":[{"name":"Hematology & Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sussman","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Smith","sequence":"additional","affiliation":[{"name":"Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampath","family":"Poreddy","sequence":"additional","affiliation":[{"name":"Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Esslinger","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Latif","sequence":"additional","affiliation":[{"name":"Hematology & Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuran","family":"Choe","sequence":"additional","affiliation":[{"name":"Radiology, University of Cincinnati, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Kharofa","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"bib1-20230822","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1245\/s10434-009-0416-6","article-title":"Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement","volume":"16","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"bib2-20230822","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.amjsurg.2007.12.017","article-title":"Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma","volume":"195","year":"2008","journal-title":"Am J Surg"},{"key":"bib3-20230822","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101","volume":"151","year":"2016","journal-title":"JAMA Surg"},{"key":"bib4-20230822","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib5-20230822","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1385\/IJGC:34:2-3:121","article-title":"Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas","volume":"34","year":"2003","journal-title":"Int J Gastrointest Cancer"},{"key":"bib6-20230822","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2014.09.010","article-title":"Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer","volume":"113","year":"2014","journal-title":"Radiother Oncol"},{"key":"bib7-20230822","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1200\/JCO.2007.15.8642","article-title":"Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib8-20230822","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","year":"2008","journal-title":"J Am Coll Surg"},{"key":"bib9-20230822","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib10-20230822","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","article-title":"The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience","volume":"22","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"bib11-20230822","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.prro.2017.10.001","article-title":"Results of a prospective phase 2 clinical trial of induction gemcitabine\/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma","volume":"8","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"bib12-20230822","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib13-20230822","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","year":"2015","journal-title":"Acta Oncol"},{"key":"bib14-20230822","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.gastro.2013.11.004","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"bib15-20230822","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"bib16-20230822","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design","volume":"87","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib17-20230822","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib18-20230822","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13566-013-0115-6","article-title":"Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor\u2013vessel relationships","volume":"2","year":"2013","journal-title":"J Radiat Oncol"},{"key":"bib19-20230822","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1998.16.1.317","article-title":"Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"bib20-20230822","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/cncr.28117","article-title":"A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer","volume":"119","year":"2013","journal-title":"Cancer"},{"key":"bib21-20230822","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.21527","article-title":"Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma","volume":"101","year":"2010","journal-title":"J Surg Oncol"},{"key":"bib22-20230822","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijrobp.2004.04.004","article-title":"Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma","volume":"60","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib23-20230822","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib24-20230822","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/mpa.0b013e31814b229a","article-title":"Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer","volume":"36","year":"2008","journal-title":"Pancreas"},{"key":"bib25-20230822","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2006.03.039","article-title":"A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma","volume":"13","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"bib26-20230822","first-page":"469","article-title":"Neural invasion in pancreatic carcinoma","volume":"1","year":"2002","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"bib27-20230822","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suronc.2017.01.007","article-title":"The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - a systematic review and meta-analysis","volume":"26","year":"2017","journal-title":"Surg Oncol"},{"key":"bib28-20230822","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.gassur.2005.09.016","article-title":"Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings","volume":"10","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"bib29-20230822","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib30-20230822","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design","volume":"20","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"bib31-20230822","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/bjs.4484","article-title":"Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma","volume":"91","year":"2004","journal-title":"Br J Surg"},{"key":"bib32-20230822","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design","volume":"104","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib33-20230822","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers2031513","article-title":"Neural invasion in pancreatic cancer: the past, present and future","volume":"2","year":"2010","journal-title":"Cancer"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:16:54Z","timestamp":1692713814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001602","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,13]]}}}